CAROLYN PETERS: Open Payments
NPI 1619363306 · SAN ANTONIO, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$601 in 19 payments from 13 companies in 2025. Trend: 2023 $210 · 2024 $1,046 · 2025 $601
Food & beverage: $518Education: $83
| Company | Payments | Amount |
|---|---|---|
| BeiGene USA, Inc. | 1 | $122 |
| SANOFI-AVENTIS U.S. LLC | 1 | $83 |
| Daiichi Sankyo Inc. | 3 | $76 |
| Merck Sharp & Dohme LLC | 2 | $58 |
| Aveo Pharmaceuticals, Inc. | 1 | $45 |
| Novartis Pharmaceuticals Corporation | 2 | $43 |
| Celgene Corporation | 2 | $43 |
| GENZYME CORPORATION | 2 | $40 |
| Janssen Biotech, Inc. | 1 | $26 |
| Ipsen Biopharmaceuticals, Inc | 1 | $18 |
Products named: BRUKINSA, SARCLISA, FOTIVDA, REBLOZYL, LYNPARZA, Vanflyta, KISQALI, Enhertu.
Industry payments across TX — which companies pay providers there.
